FEASIBILITY AND SAFETY OF ALLOGENEIC EX VIVO ACTIVATED-NK CELL INFUSION AFTER MATCHED RELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A PROSPECTIVE PHASE I TRIAL

被引：0
|
作者：
Calmels, B. [1 ]
Devillier, R. [2 ]
Guia, S. [3 ]
Mfarrej, B. [1 ]
Furst, S. [2 ]
Harbi, S. [2 ]
Granata, A. [2 ]
Faucher, C. [2 ]
Izadifar, F. [2 ]
Makni, B. [1 ]
Vicari, O. [1 ]
Lignee, P. [1 ]
Lemarie, C. [1 ]
Fauriat, C. [4 ]
Olive, D. [4 ]
Vivier, E. [3 ]
Chabannon, C. [1 ]
Ugolini, S. [3 ]
Blaise, D. [2 ]
机构：
[1] Inst Paoli Calmettes, Ctr Therapie Cellulaire, Marseille, France
[2] Inst Paoli Calmettes, Unite Transplantat & Therapie Cellulaire, Marseille, France
[3] Ctr Immunol Marseille Luminy, Marseille, France
[4] Inst Paoli Calmettes, Lab Immunomonitoring, Marseille, France
来源：
CYTOTHERAPY | 2017年 / 19卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
22
引用
收藏
页码：S16 / S16
页数：1
相关论文
共 50 条
  • [1] Feasibility and safety of allogeneic ex vivo activated-NK cell infusion after matched related hematopoietic stem cell transplantation: Preliminary results of a prospective phase I trial
    Calmels, B.
    Devillier, R.
    Guia, S.
    Mfarrej, B.
    Furst, S.
    Harbi, S.
    Granata, A.
    Faucher, C.
    Izadifar, F.
    Makni, B.
    Vicari, O.
    Lignee, P.
    Lemarie, C.
    Fauriat, C.
    Olive, D.
    Vivier, E.
    Chabannon, C.
    Ugolini, S.
    Blaise, D.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S155 - S155
  • [2] Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor
    Devillier, Raynier
    Calmels, Boris
    Guia, Sophie
    Taha, Mohammed
    Fauriat, Cyril
    Mfarrej, Bechara
    Venton, Geoffroy
    Vivier, Eric
    Olive, Daniel
    Chabannon, Christian
    Blaise, Didier
    Ugolini, Sophie
    CANCERS, 2021, 13 (11)
  • [3] Phase 1 Trial of Prophylactic Donor-Derived IL-2 Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor
    Devillier, Raynier
    Calmels, Boris
    Guia, Sophie
    Fauriat, Cyril
    Furst, Sabine
    Harbi, Samia
    Granata, Angela
    Ugolini, Sophie
    Chabannon, Christian
    Olive, Daniel
    Vivier, Eric
    Blaise, Didier
    BLOOD, 2020, 136
  • [4] Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors
    De Jong, Cornelis N.
    Meijer, Ellen
    Bakunina, Katerina
    Nur, Erfan
    Kooij, Marinus van Marwijk
    de Groot, Marco R.
    van Gelder, Michel
    Maertens, Johan A.
    Kuball, Jurgen H. E.
    Deeren, Dries
    van der Holt, Bronno
    Cornelissen, Jan J.
    Broers, Annoek E. C.
    BLOOD, 2019, 134
  • [5] Phase I Trial of Allogeneic Donor Gamma Delta T Cell Infusion Post-Hematopoietic Cell Transplantation, an Interim Safety Report
    Bejanyan, Nelli
    Elmariah, Hany
    Reid, Kayla
    Yu, Bin
    Kim, Jongphil
    Cox, Cheryl
    Lowden, Melissa
    Faramand, Rawan
    Cubitt, Christopher
    Liu, Hien
    Boucher, Justin
    Guevara, Jose Alejandro
    Sallman, David A.
    Lancet, Jeffrey
    Pidala, Joseph A.
    Karyampudi, Kumar
    Locke, Frederick L.
    Anasetti, Claudio
    Davila, Marco
    BLOOD, 2023, 142
  • [6] impact of the different approaches of in vivo T cell depletion on NK cell subsets reconstitution after allogeneic Hematopoietic Stem Cell Transplantation
    Tirefort, Y.
    Simonetta, F.
    Pradier, A.
    Bosshard, C.
    Grandjean, A. -P.
    Beauverd, Y.
    Masouridi-Levrat, S.
    Matthes, T.
    Roosnek, E.
    Chalandon, Y.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S456 - S457
  • [7] Allogeneic Hematopoietic Cell Transplantation in AML: Comparable Results After Matched or Mismatched Unrelated Versus Matched Related Transplantation.
    Federmann, Birgit
    Faul, Christoph
    Vogel, Wichard
    Kanz, Lothar
    Bethge, Wolfgang Andreas
    BLOOD, 2009, 114 (22) : 493 - 493
  • [8] Allo-reactive NK cells after HLA-matched allogeneic hematopoietic stem cell transplantation.
    Hasenkamp, Justin
    Borgerding, Andrea
    Chapuy, Bjoem
    Wulf, Gerald
    Missal, Inga
    Jung, Wolfram
    Truemper, Lorenz
    Glass, Bertram
    BLOOD, 2006, 108 (11) : 822A - 822A
  • [9] Ex-Vivo Expanded NK Cell Therapy Combined with Elotuzumab for MRD after Autologous Stem Cell Transplantation: A Phase I/II Clinical Trial in Progress
    Hagiwara, Shotaro
    Wang, Yan-Hua
    Kobayashi, Hirohito
    Kato, Yutaka
    Tanaka, Norina
    Iizuka, Yuki
    Watanabe, Aya
    Ishiyama, Midori
    Shinohara, Akihito
    Kazama, Hiroshi
    Yoshinaga, Kentaro
    Shiseki, Masayuki
    Kanno, Hitoshi
    Tanaka, Junji
    BLOOD, 2019, 134
  • [10] Donor-Derived Ex-Vivo Activated NK Cells in Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Acute Leukemia
    Cao, Xing-Yu
    Wu, Tong
    Deng, Bi-Ping
    Sun, Rui-Juan
    Lu, Yue
    Zhao, Yan-Li
    Zhang, Jian-Ping
    Zhou, Jia-Rui
    Wei, Zhi-Jie
    Tao, Xiu-Yan
    Wang, Hui
    Liu, Hong-Xing
    Lu, Dao-Pei
    Tong, Chun-Rong
    BLOOD, 2014, 124 (21)
12345